Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
The Food and Drug Administration (FDA) recently removed Eli Lily's weight-loss drug from its shortage list ... brand names Mounjaro and Zepbound, is no longer in short supply, but it means ...
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...
The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli Lilly's (NYSE: LLY) popular Mounjaro and Zepbound. However, the U.S. Food ...
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...
After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as ...
Eli Lilly’s LLY-N high profile weight ... shortages, but last quarter Lilly said it had ramped up manufacturing and was able to fill back orders at wholesalers. Now Lilly’s drugs are no longer ...
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
Eli Lilly has ben able ... versions of these popular weight-loss drugs, as the FDA allows compounding drugs when a drug is on its drug shortage list. Eli Lilly and Novo Nordisk have both ...